BioLife Solutions (BLFS) Scheduled to Post Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. BioLife Solutions has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06. BioLife Solutions had a negative net margin of 45.84% and a negative return on equity of 12.89%. The business had revenue of $31.73 million during the quarter, compared to analysts’ expectations of $29.30 million. During the same period in the previous year, the company earned ($0.27) earnings per share. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $22.88 on Wednesday. The firm has a market capitalization of $1.05 billion, a PE ratio of -16.11 and a beta of 1.85. BioLife Solutions has a 1 year low of $8.92 and a 1 year high of $24.51. The company has a current ratio of 2.89, a quick ratio of 1.77 and a debt-to-equity ratio of 0.05. The firm’s fifty day simple moving average is $21.41 and its 200 day simple moving average is $19.28.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction on Friday, June 14th. The shares were sold at an average price of $20.18, for a total value of $201,800.00. Following the sale, the chief marketing officer now directly owns 108,894 shares in the company, valued at approximately $2,197,480.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction on Friday, June 14th. The shares were sold at an average price of $20.18, for a total transaction of $201,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 108,894 shares of the company’s stock, valued at $2,197,480.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Sarah Aebersold sold 3,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the completion of the transaction, the insider now directly owns 61,683 shares in the company, valued at $1,297,193.49. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,215 shares of company stock worth $313,281. 2.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on BLFS shares. StockNews.com raised BioLife Solutions to a “sell” rating in a research report on Friday, May 10th. TD Cowen increased their price target on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Finally, Benchmark upgraded shares of BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Monday, May 13th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $23.83.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.